Evidence map›Paper›PMID 24465592›Full record

ArticlePloS one2014

Association between CASP8 -652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study.

Barbara Pardini, Paolo Verderio, Sara Pizzamiglio, Carmela Nici, Maria Valeria Maiorana, Alessio Naccarati, Ludmila Vodickova, Veronika Vymetalkova, Silvia Veneroni, Maria Grazia Daidone and 17 more

Erratum issuedAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Journal of Cancer · 2018
    Article
  5. Oncotarget · 2017
    Article
  6. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

27 authors.

Barbara PardiniGenomic Variation in Human Populations and Complex Diseases Unit, Human Genetics Foundation, Turin, Italy.
Paolo VerderioUnit of Medical Statistics, Biometry and Bioinformatics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Sara PizzamiglioUnit of Medical Statistics, Biometry and Bioinformatics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Carmela NiciFondazione Istituto Italian Foundation for Cancer Research di Oncologia Molecolare, Milan, Italy.
Maria Valeria MaioranaFondazione Istituto Italian Foundation for Cancer Research di Oncologia Molecolare, Milan, Italy.
Alessio NaccaratiMolecular and Genetic Epidemiology Unit, Human Genetics Foundation, Turin, Italy ; Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Ludmila VodickovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic ; First Medical Faculty, Charles University, Prague, Czech Republic.
Veronika VymetalkovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic ; First Medical Faculty, Charles University, Prague, Czech Republic.
Silvia VeneroniDepartment of Experimental Oncology and Molecular Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Maria Grazia DaidoneDepartment of Experimental Oncology and Molecular Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Fernando RavagnaniImmunohematology and Transfusion Medicine Service, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Tiziana BianchiAssociazione Italiana Volontari Sangue Comunale Milano, Milan, Italy.
Luis BujandaGastroenterology Department, Hospital Donostia, Networked Biomedical Research Centre for Hepatic and Digestive Diseases, Basque Country University, San Sebastián, Spain.
Angel CarracedoGalician Public Foundation of Genomic Medicine, Centro de Investigación Biomédica en Red de Enfermedades Raras, Genomics Medicine Group, Hospital Clínico, Santiago de Compostela, University of Santiago de Compostela, Galicia, Spain.
Antoni CastellsDepartment of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
Clara Ruiz-PonteGalician Public Foundation of Genomic Medicine, Centro de Investigación Biomédica en Red de Enfermedades Raras, Genomics Medicine Group, Hospital Clínico, Santiago de Compostela, University of Santiago de Compostela, Galicia, Spain.
Hans MorreauDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Kimberley HowarthMolecular and Population Genetics Laboratory and National Institute for Health Research Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Angela JonesMolecular and Population Genetics Laboratory and National Institute for Health Research Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Sergi Castellví-BelDepartment of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
Li LiDepartment of Family Medicine and Community Health and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, United States of America.
Ian TomlinsonMolecular and Population Genetics Laboratory and National Institute for Health Research Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Tom Van WezelDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Pavel VodickaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic ; First Medical Faculty, Charles University, Prague, Czech Republic.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
Paolo PeterlongoFondazione Istituto Italian Foundation for Cancer Research di Oncologia Molecolare, Milan, Italy.
EPICOLON Consortium

Funding

Obesity-Related Insulin Resistance Signaling Pathway Factors and Colon CancerR01CA136726 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LI, LI · 2009 to 2013
$2.3M
NCI NIH HHS R01 CA136726NCI NIH HHS R01CA136726Wellcome Trust 090532Wellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

The common -652 6N del variant in the CASP8 promoter (rs3834129) has been described as a putative low-penetrance risk factor for different cancer types. In particular, some studies suggested that the deleted allele (del) was inversely associated with CRC risk while other analyses failed to confirm this. Hence, to better understand the role of this variant in the risk of developing CRC, we performed a multi-centric case-control study. In the study, the variant -652 6N del was genotyped in a total of 6,733 CRC cases and 7,576 controls recruited by six different centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands collaborating to the international consortium COGENT (COlorectal cancer GENeTics). Our analysis indicated that rs3834129 was not associated with CRC risk in the full data set. However, the del allele was under-represented in one set of cases with a family history of CRC (per allele model OR = 0.79, 95% CI = 0.69-0.90) suggesting this allele might be a protective factor versus familial CRC. Since this multi-centric case-control study was performed on a very large sample size, it provided robust clarification of the effect of rs3834129 on the risk of developing CRC in Caucasians.

Indexed as

Promoter Regions, GeneticSequence DeletionAdolescentAdultAgedAged, 80 and overAllelesBase SequenceCase-Control StudiesCaspase 8Colorectal NeoplasmsFemaleHumansMaleMiddle AgedMolecular Sequence DataCASP8 protein, humanCaspase 8

Identifiers

PMID24465592
PMCPMC3897464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.